Consequently, the response to pirfenidone treatment can potentially be predicted by evaluating CTHRC1 levels in myofibroblasts, providing an avenue for identifying novel treatment options for lung fibrosis [18]. Here, CTHRC1 is linked to pulmonary fibrosis.